ReviewAdvances in experimental medicine and biology2026
Cell-Cell Fusion as a Mechanism of Immune Evasion and Metastatic Progression.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cancer cell fusion theory has emerged in the last few years as a critical yet under-recognised mechanism contributing to tumour progression and metastasis. This chapter revisits its historical foundations and explores the cellular and molecular mechanisms that underpin fusion events. The resulting tumour hybrid cells (THCs) display enhanced migratory and invasive properties and chemoresistant properties, together with profound immunomodulatory capacities. These hybrids often express immune cell markers and stem-like features, enabling them to evade immune surveillance and adapt to hostile microenvironments. Recognition of cell fusion as a driver of tumour evolution challenges classical models of metastasis and highlights the urgent need to identify biomarkers and therapeutic targets associated with fusion-derived hybrids.
Indexed as
Identifiers
42168748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.